Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease. In addition, it develops products for cardiometabolic indications. The company has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Metrics to compare | GLMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLMDPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −3.0x | −0.5x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | 0.3x | 2.3x | 2.6x | |
Price / LTM Sales | - | 8.6x | 3.2x | |
Upside (Analyst Target) | - | 609.9% | 45.3% | |
Fair Value Upside | Unlock | 3.6% | 7.4% | Unlock |